Research Progress of Epigenetic Mechanism in Acquired Resistance of Targeted Therapy in Non-small Cell Lung Cancer
Patients with oncogenic driver alterations of non-small cell lung cancer (NSCLC) can benefit from targeted therapy, but acquired resistance is inevitable ultimately. Epigenetic modifications, including DNA methylation, histone modifications, non-coding RNA-mediated regulate and chromatin remodeling,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021-10-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.34 |
| _version_ | 1818989114615136256 |
|---|---|
| author | Xin AI Yan WANG |
| author_facet | Xin AI Yan WANG |
| author_sort | Xin AI |
| collection | DOAJ |
| description | Patients with oncogenic driver alterations of non-small cell lung cancer (NSCLC) can benefit from targeted therapy, but acquired resistance is inevitable ultimately. Epigenetic modifications, including DNA methylation, histone modifications, non-coding RNA-mediated regulate and chromatin remodeling, are important mechanisms of acquired resistance in targeted therapy of NSCLC. In recent years, studies have found that epigenetic modifications can effectively reverse drug resistance. Targeted therapy combined with epigenetic modifications may become a promising therapeutic strategy. Here, we review the progress of epigenetic mechanism in acquired resistance of targeted therapy in NSCLC, hoping to provide ideas for screening dominant population and overcoming resistance. |
| first_indexed | 2024-12-20T19:33:20Z |
| format | Article |
| id | doaj.art-d490e15a7fe34449a7485d2951072f88 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-20T19:33:20Z |
| publishDate | 2021-10-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-d490e15a7fe34449a7485d2951072f882022-12-21T19:28:43ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872021-10-01241070571310.3779/j.issn.1009-3419.2021.102.34Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung CancerXin AI0Yan WANG1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaPatients with oncogenic driver alterations of non-small cell lung cancer (NSCLC) can benefit from targeted therapy, but acquired resistance is inevitable ultimately. Epigenetic modifications, including DNA methylation, histone modifications, non-coding RNA-mediated regulate and chromatin remodeling, are important mechanisms of acquired resistance in targeted therapy of NSCLC. In recent years, studies have found that epigenetic modifications can effectively reverse drug resistance. Targeted therapy combined with epigenetic modifications may become a promising therapeutic strategy. Here, we review the progress of epigenetic mechanism in acquired resistance of targeted therapy in NSCLC, hoping to provide ideas for screening dominant population and overcoming resistance.http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.34lung neoplasmstargeted therapyresistance mechanismepigenomics |
| spellingShingle | Xin AI Yan WANG Research Progress of Epigenetic Mechanism in Acquired Resistance of Targeted Therapy in Non-small Cell Lung Cancer Chinese Journal of Lung Cancer lung neoplasms targeted therapy resistance mechanism epigenomics |
| title | Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung Cancer |
| title_full | Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung Cancer |
| title_fullStr | Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung Cancer |
| title_full_unstemmed | Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung Cancer |
| title_short | Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung Cancer |
| title_sort | research progress of epigenetic mechanism in acquired resistance of
targeted therapy in non small cell lung cancer |
| topic | lung neoplasms targeted therapy resistance mechanism epigenomics |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.34 |
| work_keys_str_mv | AT xinai researchprogressofepigeneticmechanisminacquiredresistanceoftargetedtherapyinnonsmallcelllungcancer AT yanwang researchprogressofepigeneticmechanisminacquiredresistanceoftargetedtherapyinnonsmallcelllungcancer |